These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20234364)

  • 1. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.
    Coleman RE; Winter MC; Cameron D; Bell R; Dodwell D; Keane MM; Gil M; Ritchie D; Passos-Coelho JL; Wheatley D; Burkinshaw R; Marshall SJ; Thorpe H;
    Br J Cancer; 2010 Mar; 102(7):1099-105. PubMed ID: 20234364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.
    Ishikawa T; Akazawa K; Hasegawa Y; Tanino H; Horiguchi J; Miura D; Hayashi M; Kohno N
    J Surg Res; 2017 Dec; 220():46-51. PubMed ID: 29180210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study).
    Hasegawa Y; Tanino H; Horiguchi J; Miura D; Ishikawa T; Hayashi M; Takao S; Kim SJ; Yamagami K; Miyashita M; Konishi M; Shigeoka Y; Suzuki M; Taguchi T; Kubota T; Akazawa K; Kohno N;
    PLoS One; 2015; 10(12):e0143643. PubMed ID: 26633806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.
    Fasching PA; Jud SM; Hauschild M; Kümmel S; Schütte M; Warm M; Hanf V; Grab D; Krocker J; Stickeler E; Kreienberg R; Müller T; Kühn T; Wolf C; Kahlert S; Paepke S; Berghorn M; Muth M; Baier M; Wackwitz B; Schulz-Wendtland R; Beckmann MW; Lux MP
    BMC Cancer; 2014 Feb; 14():66. PubMed ID: 24499441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
    Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
    Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.
    Banys M; Solomayer EF; Gebauer G; Janni W; Krawczyk N; Lueck HJ; Becker S; Huober J; Kraemer B; Wackwitz B; Hirnle P; Wallwiener D; Fehm T
    BMC Cancer; 2013 Oct; 13():480. PubMed ID: 24128322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study.
    Winter MC; Wilson C; Syddall SP; Cross SS; Evans A; Ingram CE; Jolley IJ; Hatton MQ; Freeman JV; Mori S; Holen I; Coleman RE
    Clin Cancer Res; 2013 May; 19(10):2755-65. PubMed ID: 23515409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
    Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
    Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials.
    Kroep JR; Charehbili A; Coleman RE; Aft RL; Hasegawa Y; Winter MC; Weilbaecher K; Akazawa K; Hinsley S; Putter H; Liefers GJ; Nortier JWR; Kohno N
    Eur J Cancer; 2016 Feb; 54():57-63. PubMed ID: 26722766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
    Charehbili A; van de Ven S; Smit VT; Meershoek-Klein Kranenbarg E; Hamdy NA; Putter H; Heijns JB; van Warmerdam LJ; Kessels L; Dercksen M; Pepels MJ; Maartense E; van Laarhoven HW; Vriens B; Wasser MN; van Leeuwen-Stok AE; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR;
    Ann Oncol; 2014 May; 25(5):998-1004. PubMed ID: 24585721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
    Clyburn RD; Reid P; Evans CA; Lefley DV; Holen I
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer.
    Aft RL; Naughton M; Trinkaus K; Weilbaecher K
    Br J Cancer; 2012 Jun; 107(1):7-11. PubMed ID: 22617128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
    Eidtmann H; de Boer R; Bundred N; Llombart-Cussac A; Davidson N; Neven P; von Minckwitz G; Miller J; Schenk N; Coleman R
    Ann Oncol; 2010 Nov; 21(11):2188-2194. PubMed ID: 20444845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
    Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer.
    Jallouk AP; Paravastu S; Weilbaecher K; Aft RL
    Breast Cancer Res Treat; 2021 May; 187(1):135-144. PubMed ID: 33591469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
    Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
    J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study.
    Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Kann P
    Breast Cancer Res Treat; 2014 Apr; 144(2):343-51. PubMed ID: 24519387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.
    Fehm T; Zwirner M; Wallwiener D; Seeger H; Neubauer H
    BMC Cancer; 2012 Jul; 12():308. PubMed ID: 22824103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
    Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
    Francini F; Pascucci A; Francini E; Miano ST; Bargagli G; Ruggiero G; Petrioli R
    J Am Dent Assoc; 2011 May; 142(5):506-13. PubMed ID: 21531932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.